A close up of a device

Description automatically generated

A close up of a device

Description automatically generated

A close up of a device

Description automatically generated

A picture containing clock

Description automatically generated

**Supplementary Figure Legends**

**Suppl. Fig. 1** **β-catenin mRNA and protein levels in CGNPs at 24 and 48 hours after Shh treatment**. **(a-d).** CGNPs were grown for 24 hours in serum free medium (SFM) in the absence (Shh-) or presence (Shh+) of Shh. **a.** Normalized *β-catenin* mRNA levels shows an increase in *β-catenin* levels in the presence of Shh (n=4; \*\*p=0.0035). **b.** Normalized β-catenin protein levels in whole cell lysates did not show any difference in at 24 hrs. **c.** Normalized β-catenin protein levels in the post-nuclear supernatant (PNS) did not show any difference in the absence or presence of Shh. **d.** Normalized β-catenin protein levels in the nuclear fraction also did not show any difference. **(e-h).** CGNPs were grown for 48 hours in SFM in the absence (Shh-) or presence (Shh+) of Shh. **e.** Normalized β-catenin mRNA levels shows no difference in *β-catenin* levels in the presence of Shh. **f.** Normalized β-catenin protein levels in whole cell lysates also showed no change in the presence or absence of Shh. **g.** Normalized β-catenin protein levels in the post-nuclear supernatant (PNS) was comparable between Shh- and Shh+ conditions. **h.** Normal levels of β-catenin protein in the nuclear fraction. **i.** Western blot showing the enrichment of β-tubulin and H2B in the post-nuclear supernatant (PNS) and nuclear fraction respectively, confirming the purity of these preparations. Graph represents Mean ± SD normalized to SFM (Shh-) condition. For mRNA the β-catenin cycle time was normalized to GAPDH within each condition. All western blots were first normalized to β-tubulin within each condition for total cell lysate and the post-nuclear supernatant. For the nuclear fraction β-catenin was normalized to histone H2B. Representative western blots used for quantitation by densitomentry is shown above each graph. (n=4 for all graphs except f where n=3).

**Suppl. Fig. 2. *β-catenin* mRNA and protein levels in CGNPs at 24 and 48 hours after IGF1 and Jagged1 treatment. (a and b).** CGNPs werecultured in serum free medium (SFM) in the absence (IGF-) or presence (IGF+) of IGF1 and cultured for 24 and 48 hours. Normalized β-catenin protein levels did not show any difference in β-catenin levels in the presence of IGF1 after 24 hours (**a**) and 48 hours (**b**) compared to IGF- conditions. **(c and d).** CGNPs werecultured in SFM in the absence (Jag1-) or presence (Jag1+) of Jagged-1 and cultured for 24 (**c**) and 48 hours (**d**). Normalized β-catenin did not show any difference in β-catenin levels in the presence of Jagged-1 after 24 hours (**c**) and 48 hours (**d**) compared to Jagged1- conditions. All western blots were first normalized to β-tubulin within each condition. Graph represents Mean ± SD normalized to SFM (IGF- or Jagged1-) condition (n=4). Representative western blots used for quantitation by densitomentry is shown above each graph.

**Suppl. Fig. 3. Canonical Wnts do not regulate β-catenin levels or CGNP proliferation**. **a.** Increasing amounts of commercially purified Wnt1 (40-120 ng), Wnt3a (30-150 ng) and Wnt10b (40-120 ng) along with the entire EGL lysates prepared from 3 mouse pups (n1 to n3) were analysed by western blot. Quantification of signal intensity showed that approximately 110 ng of Wnt1, 90 ng of Wnt3a and 60 ng of Wnt10b were present in the cerebellar EGL. **b.** Quantification of Ki-67 positive cells in CGNPs grown for 72 hrs in serum free medium (SFM) supplemented with either Wnt1, Wnt3a or Wnt10b shows that these Wnts do not cause any increase in Ki67+ cells. Graph represents Mean ± SD normalized to SFM condition (n=3. Average of 600 cells counted in each n) **(c-e).** Normalized β-catenin protein levels after 24, 48 and 72 hours post treatment of CGNP cultures with either Wnt1, Wnt3a or Wnt10b show no change in response to these Wnt ligands. All western blots were first normalized to β-tubulin within each condition. Graph represents Mean ± SD normalized to SFM (Wnt1-, Wnt3a-, Wnt10b-) condition (n=5). Representative western blots used for quantitation by densitomentry is shown above each graph.

**Suppl. Fig. 4.** **Effect of Shh on Wnt pathway genes. a.** Inhibition of Wnt pathway by Dickkopf (Dkk) results in decrease in β-catenin levels in CGNPs (n=4; \*\*p=0.0043, #p=0.0135). **b.** Inhibition of Wnt pathway by Dkk in the presence of Shh does not affect β-catenin levels (n=3; \*\*p= 0.0031, $$p= 0.0075, ##p= 0.0061). **c.** Axin protein levels do not show any change in the presence or absence of Shh (n=4). **(d-g)** mRNA levels for *CK1* (d) *Dvl2* (e) *APC* (f) *GSK3β* (g) did not exhibit any change in the presence of Shh (n=4). All data are from CGNPs grown in serum free medium (SFM) for 72 hrs. Graph represents Mean ± SD normalized to SFM (Shh-). All western blots were first normalized to β-tubulin within each condition. Representative western blots used for quantitation by densitomentry is shown above each graph. For mRNA, the target gene cycle time was norm